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Inflammatory bowel diseases are characterized by chronic
intestinal inflammation at different sites. Data from animal
models as well as human patients including gene-associa-
tion studies suggest that different components of the innate
barrier function are primarily defective. These recent
advances support the evolving hypothesis that intestinal
bacteria induce inflammation predominantly as a result of a
weakened innate mucosal barrier in genetically predisposed
individuals. The mechanisms include different defects in
epithelial stem cell differentiation, defective pattern recog-
nition, autophagy, endosomal stress and others. Secretory
cells like the Paneth cell of the small intestinal crypt as well
as mucin producing goblet cells seem to be of major impor-
tance in the initial stages of the disease process. This talk
will discus our current understanding of the primary events
of disease and also outline consequences for future thera-
peutic consequences. In summary, there is a need for thera-
peutic avenues aimed at restoring antimicrobial barrier
function to prevent a bacterial-triggered inflammatory
response.
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